We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
TERIFLUNOMIDE INTAS, TERIFLAGIO, TERINTAS (Accord Healthcare Pty Ltd)
Product name
TERIFLUNOMIDE INTAS, TERIFLAGIO, TERINTAS
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
141 working days (255)
Active ingredients
teriflunomide
Registration type
New generic medicine
Indication
TERIFLUNOMIDE INTAS, TERIFLAGIO, TERINTAS (film-coated tablets) are indicated for the treatment of patients with relapsing forms of Multiple Sclerosis to reduce the frequency of clinical relapses and to delay the progression of physical disability.